Margaret Rank, M.D.
"The AMAS test is a powerful diagnostic and prognostic tool when used
properly. Measuring the levels of antibodies to Malignin, it can be
used to diagnose sub-clinical cancer. That is, it can detect very
small tumors before they become evident by usual diagnostic tests and
physical exam. Small cancers can often be treated for cure with either
conventional means or natural means. This is truly one of the weapons
against cancer that is grossly underutilized.
Use of the AMAS can prevent unnecessary procedures or prompt further investigation. For instance, statistics show that up to nine of 10 biopsies done because of an "abnormal" mammogram, are done for non-cancerous lesions. Also, many of the pathology reports of breast biopsies read as cancerous actually represent benign (non-cancerous) conditions. If the AMAS were used in these cases, many unnecessary, anxiety provoking surgical procedures could be avoided. Additionally, misdiagnoses of breast cancer that often lead to chemotherapy and radiation treatment, could be avoided in many cases. The mammogram is far too sensitive (it detects "disease" frequently when there is none), very non-specific (it can't always separate benign from malignant disease) and can deal a potentially cancer-causing dose of radiation. I have replaced this by breast MRI and/or the AMAS test. I have helped many of my patients avoid unnecessary surgery or biopsies with judicious use of this test.
The AMAS, in conjunction with other clinical studies including assessment of the immune system, can help follow the progress of treatment or the need for intensification of therapy when dealing with a known cancer. It also assists with prognosis, detection of tumor progression or regression, and efficacy of a particular treatment protocol.
To patients, I suggest strongly that they find a competent clinician familiar with the AMAS test and its interpretation to assess their individual needs and guide them in their decision-making."
Margaret Rank, M.D.
Melbourne, FL
Leave a comment